Table 3.
IC50 of chemotherapeutic agent or combined with knockdown of cIAP1 or cIAP2 for DAOY and D283MED cells
| Cell line | Treatment | IC50 | P‐valuea |
|---|---|---|---|
| DAOY | Vincristine | 3.47 ± 0.28 nmol/L | |
| NT siRNA + Vincristine | 4.78 ± 0.46 nmol/L | ||
| XIAP siRNA + Vincristine | 2.76 ± 0.09 nmol/L | 0.0259 | |
| cIAP1/2 siRNA + Vincristine | 2.43 ± 0.33 nmol/L | 0.0278 | |
| Cisplatin | 0.74 ± 0.06 μmol/L | ||
| NT siRNA + Cisplatin | 1.31 ± 0.13 μmol/L | ||
| XIAP siRNA + Cisplatin | 0.28 ± 0.01 μmol/L | 0.0079 | |
| cIAP1/2 siRNA + Cisplatin | 0.21 ± 0.01 μmol/L | 0.0070 | |
| D283MED | Vincristine | >5 nmol/L | |
| NT siRNA + Vincristine | 4.44 ± 0.29 nmol/L | ||
| XIAP siRNA + Vincristine | 0.37 ± 0.05 nmol/L | 0.0026 | |
| cIAP1/2 siRNA + Vincristine | 0.44 ± 0.05 nmol/L | 0.0027 | |
| Cisplatin | >2.5 μmol/L | ||
| NT siRNA + Cisplatin | 2.39 ± 0.13 μmol/L | ||
| XIAP siRNA + Cisplatin | 0.17 ± 0.10 μmol/L | 0.0027 | |
| cIAP1/2 siRNA + Cisplatin | 0.31 ± 0.03 μmol/L | 0.0021 |
a
P‐value is calculated after comparing to nontargeting siRNA (NT siRNA) treatment.